ASH 2014: Clinical trial shows that chimeric antigen receptor (CAR) T-cell therapy prolongs remission in paediatric relapsed or refractory acute lymphocytic leukaemia

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Stephan Grupp (Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA) presents the results of a study that suggests chimeric antigen receptor (CAR) T cells targeting CD19 (CTL019) can elicit durable remissions in paediatric relapsed or refractory acute lymphocytic leukaemia.